Browse studies

Find your next paid study

270 recruiting studies matching your filters

Newest first Highest paying

Phase 1

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.

Acute Myeloid Leukemia

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06284486

Phase 1

Phase 1 Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

The goal of this all-oral combination is to deliver safe and effective therapy for the largest portion of AML subtypes (NPM1mt, KMT2Ar, NUP98r \~ 40-45%).

Acute Myeloid Leukemia

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06769490

Phase 1

A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML

This phase Ib/II trial studies the best dose and side effects of venetoclax and how well it works when given with combination chemotherapy in treating patients…

High Risk Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT03214562

Phase 2

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia

This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochlori…

Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1+7 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT00801489

Phase 1

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Therapy

This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysp…

Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+15 more

Estimated

~$10 – $6,250

Phase 2

A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms

This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patient…

Acute Myeloid LeukemiaEssential ThrombocythemiaMyelodysplastic Syndrome+6 more

Estimated

~$10 – $6,250

University of WashingtonNCT04282187

Phase 1

Phase I Study of Autologous CD4+ and CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Treatment of MRD-Positive AML

This phase I trial tests the safety, side effects and best dose of FH-WT1-E50 TCR T cells with azacitidine for the treatment of minimal residual disease (MRD) …

Acute Myeloid Leukemia

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT07645469

Phase 1

Phase 1 Study of Anti-FLT3 Chimeric Antigen Receptor-redirected T Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety. Up to 1…

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Estimated

~$10 – $8,750

Hemogenyx Pharmaceuticals LLCNCT06786533

Phase 3

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients wi…

Acute Myeloid Leukemia

Estimated

~$10 – $7,500

Children's Oncology GroupNCT04293562

Observational

Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults With Acute Myeloid Leukemia or High-Grade Myeloid Neoplasms: A Randomized Pilot Study

This clinical trial studies whether less fit adults with acute myeloid leukemia (AML) or myeloid neoplasms are willing to let a computer program decide (random…

Acute Leukemia of Ambiguous LineageAcute Myeloid LeukemiaMyeloid Neoplasm

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT07094750

Phase 2

A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients wit…

Acute Myeloid Leukemia

Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT05955261

Phase 1

CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study

This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin,…

Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+6 more

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT04375631